4SC 202

Drug Profile

4SC 202

Alternative Names: 4SC-202

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies
  • Preclinical Small cell lung cancer

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in indication) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 May 2016 Chemical information added
  • 07 Apr 2016 4SC 202 is available for licensing as of 30 Mar 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top